Wilson Therapeutics AB (Publ) Year-End Report 2017

Feb 21, 2018

“After a highly successful year, we are excited that we now have entered the pivotal phase of development for WTX101. Backed by positive Phase 2 data, an experienced international team and a solid balance sheet, we are very well positioned to advance WTX101 through Phase 3.” – Jonas Hansson, CEO.

October 1 – December 31, 2017

  • Net sales amounted to SEK 0.0 M (0.0)
  • Loss for the period was SEK 52.8 M (loss: 34.1)
  • Loss per share, before and after dilution, totaled SEK 2.00 (loss: 1.33)
  • At December 31, cash and cash equivalents amounted to SEK 468.7 M (386.6)

January 1 – December 31, 2017

  • Net sales amounted to SEK 0.0 M (0.0)
  • Loss for the period was SEK 168.2 M (loss:115.2)
  • Loss per share, before and after dilution, totaled SEK 6.50 (loss: 6.84)
  • The board of directors proposes that no dividend be paid for 2017

Significant events during 2017

  • Extraordinary general meeting held in January 2017 resolved to implement the long-term incentive program LTIP 2016
  • Data from the successfully completed Phase 2 trial were presented at major scientific conferences
  • Board strengthened by the appointments of Dr. Birgitte Volck and Dr. Björn Odlander
  • The AGM resolved to implement the long-term incentive program LTIP 2017
  • US Orphan Drug Designation granted for WTX101 for the treatment of ALS
  • Phase 2 data published in The Lancet Gastroenterology & Hepatology
  • Preliminary long-term data from the extension phase of the Phase 2 study presented at scientific conference
  • Agreement reached with the FDA and EMA to initiate pivotal Phase 3 FOCuS study
  • A directed share issue raised approximately SEK 244 M before issue costs
  • WTX101 granted Fast Track designation by the FDA for the treatment of Wilson Disease

Significant events after the end of the reporting period

  • First patient enrolled in pivotal Phase 3 FOCuS trial
  • New patents filed

Invitation to telephone conference

All interested parties are invited to participate in a web-cast telephone conference today February 21 at 10:00 CET. The event will be hosted by Wilson Therapeutics’ CEO Jonas Hansson and CFO Anders Martin-Löf and will include a presentation in English.The live webcast and a recorded on-demand version including the presentation material will be accessible at: https://tv.streamfabriken.com/wilson-therapeutics-q4-2017. Questions can be asked in writing via the webcast or verbally via the conference call.

To participate in the conference call, please call one of the following numbers:

  • SE: +46 8 566 426 69
  • UK: +44 203 008 9817
  • US: +1 855 831 5944

The presentation material will also be published before the conference starts on Wilson Therapeutics’ website www.wilsontherapeutics.com, under Media & Investors/Presentations. The webcast, and later the recorded version of the webcast and the conference call, will also be accessible via Wilson Therapeutics’ website.

About Wilson Therapeutics

Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare copper-mediated disorders. Wilson Therapeutics’ lead product, WTX101, is in Phase 3 development as a novel treatment for Wilson Disease. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX.

Visit www.wilsontherapeutics.com for more information.

For further information contact

Jonas Hansson, CEO, Wilson Therapeutics AB
Telephone: +46 8 796 00 00
Email: jonas.hansson@wtx.se

Wilson Therapeutics AB (publ)
Corp. Reg. No. 556893-0357
Kungsgatan 3
SE-111 43 Stockholm
The information in the year-end report is information that Wilson Therapeutics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 07.00 CET on February 21, 2017.